John is an analyst working on biotech, pharma, medical device and diagnostics companies. As founding CEO of Physiomics, he devised the strategy, raised funds and took the company to AIM in 2004. At Greig Middleton, John was director in charge of the pharma and biotech analyst team, and worked with corporate finance on fund-raising, IPOs and corporate restructuring. He has an industry background in sales and marketing with GE Healthcare and AstraZeneca and is co-author of a number of scientific publications. He has a PhD in Organic Chemistry as well as MBA degrees.